Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC.

Florence Marteau,Brooke Harrow,Christine McCarthy,Joel Wallace,Alisha Monnette,Yunfei Wang,Gurjyot K. Doshi

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 2|浏览3

暂无评分

摘要

293Background: Checkpoint inhibitors (CPIs) are a treatment option for patients with metastatic renal cell carcinoma (mRCC), but there is limited clinical data on the efficacy of targeted therapies...

查看译文

关键词

metastatic renal cell carcinoma,cpi treatment,cell carcinoma,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要